Role of metabotropic glutamate receptor 5 in the procholinergic effects of neuropsychotherapeutic compounds

Synapse

Volumn 62, Issue 12, 2008, Pages 940-943

  Tzavara, Eleni T ^a,b   Wade, Mark R ^a   Davis, Richard J ^a   El Khoury, Marie Anne ^b   Nomikos, George G ^a,c  

^a ELI LILLY AND COMPANY   (United States)

^b INSERM   (France)

^c Cannasat Therapeutics   (Canada)

Author keywords

Acetylcholine; Atomoxetine; Clozapine; Dihydrexidine; In vivo microdialysis; Prefrontal cortex; SR141716A

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; ACETYLCHOLINE; ATOMOXETINE; CLOZAPINE; DIHYDREXIDINE; METABOTROPIC RECEPTOR 5; RIMONABANT;

ACETYLCHOLINE BRAIN LEVEL; ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ARTICLE; BRAIN CORTEX; CHOLINERGIC ACTIVITY; CONTROLLED STUDY; DRUG EFFECT; IN VIVO STUDY; MICRODIALYSIS; NEUROPSYCHIATRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PSYCHOPHARMACOLOGY; RAT;

ACETYLCHOLINE; ANIMALS; CEREBRAL CORTEX; CHOLINERGIC AGENTS; PSYCHOTROPIC DRUGS; RATS; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 56549108746     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20560     Document Type: Article

References (14)

1. Balschun D, Wetzel W. 2002. Inhibition of mGluR5 blocks hippocampal LTP in vivo and spatial learning in rats. Pharmacol Biochem Behav 73:375-380.
2. Balschun D, Zuschratter W, Wetzel W. 2006. Allosteric enhancement of metabotropic glutamate receptor 5 function promotes spatial memory. Neuroscience 142:691-702.
3. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW. 2002. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699-711.
4. Gasparini F, Lingenhöhl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, Biollaz M, Allgeier H, Heckendorn R, Urwyler S, Varney MA, Johnson EC, Hess SD, Rao SP, Sacaan AI, Santori EM, Veliçelebi G, Kuhn R. 1999. 2-Methyl-6-(phenylethynyl) pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38:1493-1503.
5. Kinney GG, Burno M, Campbell UC, Hernandez LM, Rodriguez D, Bristow LJ, Conn PJ. 2003. Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exp Ther 306:116-123.
6. Li X, Need AB, Baez M, Witkin JM. 2006. Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J Pharmacol Exp Ther 319:254-259.
7. Shirazi-Southall S, Rodriguez DE, Nomikos GG. 2002. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 26:583-594.
8. Spooren WP, Gasparini F, Salt TE, Kuhn R. 2001. Novel allosteric antagonists shed light on mglu(5) receptors and CNS disorders. Trends Pharmacol Sci 22:331-337.
9. Steele TD, Hodges DB Jr, Levesque TR, Locke KW. 1997. D1 agonist dihydrexidine releases acetylcholine and improves cognitive performance in rats. Pharmacol Biochem Behav 58:477-483.
10. Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, Witkin JM, Nomikos GG. 2003. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: Implications for therapeutic actions. Br J Pharmacol 138:544-553.
11. Tzavara ET, Bymaster FP, Overshiner CD, Davis RJ, Perry KW, Wolff M, McKinzie DL, Witkin JM, Nomikos GG. 2006. Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine. Mol Psychiatry 11:187-195.
12. Wade MR, Nomikos GG. 2005. Tolerance to the procholinergic action of the D1 receptor full agonist dihydrexidine. Psychopharmacology (Berl) 182:393-399.
13. Westerink BH, Kawahara Y, de Boer P. 2001. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur J Pharmacol 412:127-138.
14. Witkin JM, Tzavara ET, Davis RJ, Li X, Nomikos GG. 2005. A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders. Trends Pharmacol Sci 26:609-617.